Condition: Rheumatoid Arthritis · Sponsor: Galvani Bioelectronics
This study will evaluate the safety and tolerability of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). Five participants will be implanted with the device and receive neurostimulation for 12 weeks.
This description comes directly from the study's public registry record.
Operations Director · +44 (0)800 3688514 · clinical@galvani.bio
Always discuss trial participation with your own doctor first.
| Academic Medical Center (AMC) Dept of Rheumatology & Clinical Immunology | Amsterdam, Netherlands | Recruiting |
| Greater Glasgow Health Board | Glasgow, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04955899